Editas Surpasses Therapeutic Gene Editing Threshold in New Preclinical Data
Editas Medicine, Inc. (NASDAQ:EDIT) ranks among the best CRISPR stocks to buy. At the European Hematology Association 2025 Congress on June 12, Editas Medicine, Inc.
Posts Tagged ‘NASDAQ:EDIT’
Top 10 CRISPR Stocks to Buy Now
Innovation is a hallmark of the biopharmaceutical sector, which is fueled by the demand for novel therapies to address unresolved medical needs.
Top 11 CRISPR Stocks to Invest In
The pharmaceutical industry is buzzing with innovation, driven by the need for new treatments, tackling unmet medical challenges, and leveraging cutting-edge technologies like...
10 Most Promising Gene Editing Stocks to Buy According to Hedge Funds
The pharmaceutical industry remains a hub of patent innovation, driven by evolving treatment paradigms, unmet medical needs, and the rising influence of technologies like pharmacogenomics...
Editas Medicine, Inc. (NASDAQ:EDIT) Q2 2024 Earnings Call Transcript
Editas Medicine, Inc. (NASDAQ:EDIT) Q2 2024 Earnings Call Transcript August 7, 2024Editas Medicine, Inc. misses on earnings expectations.
10 Best Biotech Penny Stocks to Buy Now
In 2024, the healthcare industry has been doing well, encouraging investors to look into new and exciting opportunities.
Top 10 Small-Cap Stocks with Highest Upside Potential
Small-cap stocks are companies with a market capitalization of somewhere between $250 million and $2 billion.
Editas Medicine, Inc. (NASDAQ:EDIT) Q1 2024 Earnings Call Transcript
Editas Medicine, Inc. misses on earnings expectations. Reported EPS is $-0.76 EPS, expectations were $-0.63. Editas Medicine, Inc.
12 Under-the-Radar Stocks With Massive Upside for 2024
In this piece, we will take a look at the 12 under the radar stocks with massive upside for 2024.
Editas Medicine, Inc. (NASDAQ:EDIT) Q4 2023 Earnings Call Transcript
Editas Medicine, Inc. beats earnings expectations. Reported EPS is $-0.23, expectations were $-0.52.
Editas Medicine, Inc. (NASDAQ:EDIT) Q4 2023 Earnings Call Transcript
Editas Medicine, Inc. beats earnings expectations. Reported EPS is $-0.23, expectations were $-0.52.
Top 11 CRISPR Stocks To Invest In
In this article, we discuss the top 11 CRISPR stocks to invest in.
12 Best Genomics Stocks To Buy Now
In this piece, we will take a look at the 12 best genomics stocks to buy now.
Editas Medicine, Inc. (NASDAQ:EDIT) Q3 2023 Earnings Call Transcript
Operator: Good morning, and welcome to Editas Medicine's Third Quarter Conference Call. All participants are now in listen-only mode.
Top 20 Genomics Companies in the World
In this piece, we will take a look at the top 20 genomics companies in the world.
Editas Medicine, Inc. (NASDAQ:EDIT) Q2 2023 Earnings Call Transcript
Operator: Good morning and welcome to Editas Medicine's Second Quarter Conference Call. There will be a question-and-answer session at the end of this call.
10 DNA Stocks Billionaires Are Loading Up On
In this article, we discuss 10 DNA stocks that billionaires love.
Editas Medicine, Inc. (NASDAQ:EDIT) Q1 2023 Earnings Call Transcript
Operator: Good morning, and welcome to Editas Medicine’s First Quarter Conference Call. All participants are now in a listen-only mode.
12 Gene Editing Stocks With the Best Long-Term Potential
In this article, we will take a look at the 12 gene editing stocks with the best long-term potential.
Top 10 CRISPR Stocks To Buy
Molecular biology, genetics, and genomics are in a significant period in history where technical capabilities and methods enable the editing of specific DNA segments and base ...
11 Most Promising Gene Editing Stocks According to Analysts
In this article, we will take a look at the 11 most promising gene editing stocks according to analysts.
Editas Medicine, Inc. (NASDAQ:EDIT) Q4 2022 Earnings Call Transcript
Operator: Good morning and welcome to Editas Medicine's Fourth Quarter and Full-year 2022 Conference Call. All participants are now in a listen-only mode.
5 Tech Stocks To Sell Now According to Cathie Wood
In this article, we will take a look at the 5 tech stocks to sell now according to Cathie Wood.
10 Most Promising Gene Therapy Companies to Watch
In this piece, we will take a look at the ten most promising gene therapy companies to watch.
10 Best Gene Editing Stocks To Buy
A report by The Wall Street Journal dated September 16 suggests that Intellia Therapeutics, Inc.
Jim Cramer Says You Should Sell These 10 Stocks
In this article, we discuss the 10 stocks that Jim Cramer says you should sell.
10 Genomics Stocks in Cathie Wood’s Portfolio That Are Underperforming
In this article, we discuss 10 genomics stocks in Cathie Wood’s portfolio that are underperforming.
5 Stocks to Sell According to Motley Fool
Below is the list of 5 stocks to sell according to Motley Fool.
10 Stocks to Sell According to Motley Fool
In this article, we examined Motley Fool Asset Management's approach to investing in stocks. We also reviewed 10 stocks to sell according to Motley Fool.
Here is What Hedge Funds Think About Editas Medicine, Inc. (EDIT)
The 800+ hedge funds and famous money managers tracked by Insider Monkey have already compiled and submitted their 13F filings for the second quarter, which unveil their equity...
10 Best Genomics Stocks to Buy Now
In this article, we will discuss the 10 best genomics stocks to buy now.
Cathie Wood Portfolio: 5 Biggest Losers
In this article, we discuss the 5 biggest losers in the stock portfolio of Cathie Wood.
Hedge Funds Are Selling Editas Medicine, Inc. (EDIT)
While the market driven by short-term sentiment influenced by the accommodative interest rate environment in the US, virus news and stimulus spending, many smart money investors...
Cathie Wood’s Top 5 Small-Cap Stock Picks
In this article, we discuss Cathie Wood’s top 5 small-cap stock picks.
10 Best Up and Coming Stocks to Invest In
In this article, we discuss the 10 best up and coming stocks to invest in.
Hedge Funds Are Crazy About Editas Medicine, Inc. (EDIT)
How do you pick the next stock to invest in? One way would be to spend days of research browsing through thousands of publicly traded companies.
15 Fastest Growing Biotech Companies in the US
In this article we talk about 15 fastest growing biotech companies in the US.
Is EDIT A Good Stock To Buy Now?
After several tireless days we have finished crunching the numbers from nearly 817 13F filings issued by the elite hedge funds and other investment firms that we track at Insider...
Hedge Funds Have Never Been This Bullish On Editas Medicine, Inc. (EDIT)
At the end of February we announced the arrival of the first US recession since 2009 and we predicted that the market will decline by at least 20% in (see why hell is coming).
Do Hedge Funds Love Editas Medicine, Inc. (EDIT)?
At the end of February we announced the arrival of the first US recession since 2009 and we predicted that the market will decline by at least 20% in (Recession is Imminent: We...
Did Hedge Funds Drop The Ball On Editas Medicine, Inc. (EDIT) ?
We know that hedge funds generate strong, risk-adjusted returns over the long run, therefore imitating the picks that they are collectively bullish on can be a profitable strategy...
Is Editas Medicine, Inc. (EDIT) Going to Burn These Hedge Funds?
We are still in an overall bull market and many stocks that smart money investors were piling into surged through October 17th.
Is Editas Medicine, Inc. (EDIT) A Good Stock To Buy?
The 700+ hedge funds and famous money managers tracked by Insider Monkey have already compiled and submitted their 13F filings for the first quarter, which unveil their equity...
Here is What Hedge Funds Think About Editas Medicine, Inc. (EDIT)
Is Editas Medicine, Inc. (NASDAQ:EDIT) a good investment right now? We check hedge fund and billionaire investor sentiment before delving into hours of research.
Is Editas Medicine, Inc. (EDIT) A Good Stock To Buy?
Hedge Funds and other institutional investors have just completed filing their 13Fs with the Securities and Exchange Commission, revealing their equity portfolios as of the end...
Is Editas Medicine, Inc. (EDIT) A Good Stock To Buy?
Hedge funds and large money managers usually invest with a focus on the long-term horizon and, therefore, short-lived dips on the charts, usually don't make them change their ...
Top Performing Investor Adds Editas Medicine (EDIT), Sienna Biopharmaceuticals (SNNA) to Its Portfolio
You might have heard about Wildcat Capital Management and Leonard Potter before, although they are not as widely covered by financial websites like Warren Buffett, Carl Icahn, ...
3 Small-Cap Biotech Stocks That Could be Poised to Explode
With the threat of severe drug pricing regulations behind it for now, the biotech sector has launched a rally in recent days, with the iShares NASDAQ Biotechnology Index (ETF) (...
13D Filing: Polaris Venture Partners VI, L.P. and Editas Medicine Inc (EDIT)
The remainder of this cover page shall be filled out for a reporting persons initial filing on this form with respect to the subject class of securities, and for any subsequent...
10 Most Interesting Companies In The World
If you were to draw up a list of the most interesting companies in the world, what would it look like? What exactly makes a company interesting to other people? Perhaps it's the...
